bioAffinity Technologies, Inc. (BIAF)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Net revenue | 1,269,483 | 2,350,386 | 2,397,652 | |
| Selling, general and administrative | 2,214,561 | 2,364,592 | 2,472,775 | |
| Research and development | 311,372 | 274,497 | 402,433 | |
| Depreciation and amortization | 113,229 | 151,298 | 151,070 | |
| Direct costs and expenses | 1,016,602 | 1,440,158 | 1,407,710 | |
| Clinical development | 129,279 | 93,705 | 51,462 | |
| Total operating expenses | 3,785,043 | 4,324,250 | 4,485,450 | |
| Loss from operations | -2,515,560 | -1,973,864 | -2,087,798 | |
| Other expense | - | - | 1 | |
| Other income | 38,053 | 9,683 | - | |
| Other expense | 483,043 | 14,697 | - | |
| Interest income | 2,025 | 2,228 | 5,186 | |
| Interest expense | 10,460 | 21,631 | 22,249 | |
| Change in fair value of warrants issued | 1,062,818 | - | - | |
| Total other income (expense), net | -1,516,243 | -24,417 | -17,062 | |
| Net loss before provision for income tax expense | -4,031,803 | -1,998,281 | -2,104,860 | |
| Income tax expense | 28,984 | 2,559 | 5,419 | |
| Net loss | -4,060,787 | -2,000,840 | -2,110,279 | |
| Net loss per common share, basic | -0.17 | -0.16 | -0.19 | |
| Net loss per common share, diluted | -0.17 | -0.16 | -0.19 | |
| Weighted average common shares outstanding, basic | 24,021,546 | 12,391,867 | 11,389,308 | |
| Weighted average common shares outstanding, diluted | 24,021,546 | 12,391,867 | 11,389,308 | |